Skip to main content
SpringerLink
Log in
Book cover

New Concepts in Diagnosis and Therapy of Pancreatic Adenocarcinoma pp 123–136Cite as

The Locally Advanced Nonmetastatic Cancer

  • Chapter
  • First Online:

  • 903 Accesses

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

Abstract

At the time of diagnosis, around 20% of patients present with a resectable tumor, 50% with a metastatic disease, and 30% with a locally advanced tumor, unresectable because of superior mesenteric artery (SMA) or celiac encasement but nonmetastatic. Despite advances in chemoradiation (CRT) and improved systemic chemotherapeutic agents, those who present with locally advanced disease suffer both from high rates of distant metastatic failure and local progression, with median survival time ranging from 5 to 11 months. In the past 30 years, modest improvements in median survival have been attained for patients with locally advanced tumors treated by CRT or chemotherapy (CT) protocols. However, no significant impact on long-term survival has been accomplished. Optimal therapy for patients with locally advanced pancreatic carcinoma remains controversial. A recent systematic review concluded that there is no standard for the treatment of locally advanced pancreatic cancers, but two options: gemcitabine-based CT or CRT. These approaches are complementary and both should be considered. An induction CT followed by a CRT for nonprogressive patients is a promising strategy whose validation is ongoing in a phase III trial.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Andre T, Balosso J et al (2000) Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys 46:903–911

    Article  PubMed  CAS  Google Scholar 

  • Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA (2004) Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59:454–459

    Article  PubMed  CAS  Google Scholar 

  • Boz G, De Paoli A, Innocente R, Rossi C, Tosolini G, Pederzoli P, Talamini R, Trovo MG (2001) Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 51:736–740

    Article  PubMed  CAS  Google Scholar 

  • Brown MW, Ning H, Arora B, Albert PS, Poggi M, Camphausen K, Citrin D (2006) A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 65:274–283

    Article  PubMed  Google Scholar 

  • Burris HA III, Moore MJ et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  • Chauffert B, Mornex F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592–1599

    Article  PubMed  CAS  Google Scholar 

  • Chung HW, Bang SM, Park SW, Chung JB, Kang JK, Kim JW, Seong JS, Lee WJ, Song SY (2004) A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60:1494–1501

    Article  PubMed  CAS  Google Scholar 

  • Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62:1345–1350

    Article  PubMed  CAS  Google Scholar 

  • Crane CH, Antolak JA et al (2001) Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30:123–132

    Article  PubMed  CAS  Google Scholar 

  • Crane CH, Abbruzzese JL et al (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52:1293–1302

    Article  PubMed  CAS  Google Scholar 

  • Crane CH, Ellis LM et al (2006) Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24:1145–1151

    Article  PubMed  CAS  Google Scholar 

  • Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG (2009) Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 27:4096–4102

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • De Paoli A, Chiara S et al (2006) Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 17:246–251

    Article  PubMed  Google Scholar 

  • Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O’Reilly EM (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86–91

    Article  PubMed  CAS  Google Scholar 

  • Earle JD, Foley JF, Wieand HS, Kvols LK, McKenna PJ, Krook JE, Tschetter LK, Schutt AJ, Twito DI (1994) Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 28:207–211

    Article  PubMed  CAS  Google Scholar 

  • El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21:2920–2925

    Article  PubMed  CAS  Google Scholar 

  • Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159

    Article  PubMed  CAS  Google Scholar 

  • Gastrointestinal Tumor Study Group (1985) Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56:2563–2568

    Article  Google Scholar 

  • Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80:751–755

    Article  Google Scholar 

  • Goldstein D, Van Hazel G et al (2007) Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 97:464–471

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Gorski DH, Beckett MA et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378

    PubMed  CAS  Google Scholar 

  • Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK (1981) Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 32:164–165

    PubMed  CAS  Google Scholar 

  • Heinemann V, Quietzsch D et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946–3952

    Article  PubMed  CAS  Google Scholar 

  • Hoyer M, Roed H et al (2005) Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76:48–53

    Article  PubMed  Google Scholar 

  • Huguet F, Andre T et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331

    Article  PubMed  CAS  Google Scholar 

  • Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27:2269–2277

    Article  PubMed  CAS  Google Scholar 

  • Iannitti D, Dipetrillo T et al (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570–575

    Article  PubMed  CAS  Google Scholar 

  • Ishii H, Okada S et al (1997) Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79:1516–1520

    Article  PubMed  CAS  Google Scholar 

  • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62

    Article  PubMed  CAS  Google Scholar 

  • Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378

    PubMed  CAS  Google Scholar 

  • Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA (2007) A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68:809–816

    Article  PubMed  CAS  Google Scholar 

  • Koong AC, Le QT et al (2004) Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58:1017–1021

    Article  PubMed  Google Scholar 

  • Koong AC, Christofferson E et al (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63:320–323

    Article  PubMed  Google Scholar 

  • Krempien RC, Munter MW et al (2006) Phase II study evaluating trimodal therapy with cetuximab intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer [ISRCTN56652283]. J Clin Oncol (Meeting Abstracts) 24:4100

    Google Scholar 

  • Krishnan S, Rana V et al (2007) Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110:47–55

    Article  PubMed  Google Scholar 

  • Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, Pisters PW, Evans DB (1998) Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 85:611–617

    Article  PubMed  CAS  Google Scholar 

  • Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD, Yen SH (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57:98–104

    Article  PubMed  CAS  Google Scholar 

  • Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH, Alberts SR, Benson AB (2008) A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol (Meeting Abstracts) 26:4506

    Google Scholar 

  • Louvet C, Andre T et al (2001) Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 12:675–679

    Article  PubMed  CAS  Google Scholar 

  • Louvet C, Andre T et al (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512–1518

    Article  PubMed  CAS  Google Scholar 

  • Louvet C, Labianca R et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516

    Article  PubMed  CAS  Google Scholar 

  • Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R (2004) Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59:445–453

    Article  PubMed  Google Scholar 

  • Minn AY, Schellenberg D et al (2009) Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment. Am J Clin Oncol 32:364–368

    Article  PubMed  Google Scholar 

  • Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867

    Article  PubMed  CAS  Google Scholar 

  • Moertel CG, Frytak S et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710

    Article  PubMed  CAS  Google Scholar 

  • Moore MJ, Goldstein D et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966. doi:10.1200/JCO.2006.07.9525

    Article  PubMed  CAS  Google Scholar 

  • Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801–808

    Article  PubMed  CAS  Google Scholar 

  • O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–507

    Article  PubMed  Google Scholar 

  • Pipas JM, Zaki B et al (2006) Cetuximab, intensity-modulated radiotherapy (IMRT), and twice-weekly gemcitabine for pancreatic adenocarcinoma. J Clin Oncol (Meeting Abstracts) 24:14056

    Google Scholar 

  • Poen JC, Collins HL et al (1998) Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Int J Radiat Oncol Biol Phys 40:93–99

    Article  PubMed  CAS  Google Scholar 

  • Poplin E, Feng Y et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, Zerbi A, Di Carlo V, Villa E (2001) Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 19:2679–2686

    PubMed  CAS  Google Scholar 

  • Rich TA, Lokich JJ, Chaffey JT (1985) A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy. J Clin Oncol 3:402–406

    PubMed  CAS  Google Scholar 

  • Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ (2004a) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27:51–56

    Article  PubMed  CAS  Google Scholar 

  • Rich TA, Shepard RC, Mosley ST (2004b) Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214–2232

    Article  PubMed  CAS  Google Scholar 

  • Rocha Lima CM, Green MR et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783

    Article  PubMed  CAS  Google Scholar 

  • Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, Kvols LK, McIlrath DC (1988) External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61:1110–1116

    Article  PubMed  CAS  Google Scholar 

  • Safran H, Akerman P, Cioffi W, Gaissert H, Joseph P, King T, Hesketh PJ, Wanebo H (1999) Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol 9:53–57

    PubMed  CAS  Google Scholar 

  • Saif MW, Eloubeidi MA et al (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23:8679–8687

    Article  PubMed  CAS  Google Scholar 

  • Schellenberg D, Goodman KA et al (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72:678–686

    Article  PubMed  CAS  Google Scholar 

  • Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T (2002) Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53:146–150

    Article  PubMed  CAS  Google Scholar 

  • Stathopoulos GP, Mavroudis D et al (2001) Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 12:101–103

    Article  PubMed  CAS  Google Scholar 

  • Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2007a) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615

    Article  PubMed  Google Scholar 

  • Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, Ghaneh P (2007b) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96:1183–1190

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Vaishampayan UN, Ben-Josef E, Philip PA, Vaitkevicius VK, Du W, Levin KJ, Shields AF (2002) A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 53:675–679

    Article  PubMed  CAS  Google Scholar 

  • Van Cutsem E, van de Velde H et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438

    Article  PubMed  CAS  Google Scholar 

  • van der Geld YG, van Triest B, Verbakel WF, van Sornsen de Koste JR, Senan S, Slotman BJ, Lagerwaard FJ (2008) Evaluation of four-dimensional computed tomography-based intensity-modulated and respiratory-gated radiotherapy techniques for pancreatic carcinoma. Int J Radiat Oncol Biol Phys 72:1215–1220

    Google Scholar 

  • Whittington R, Solin L, Mohiuddin M, Cantor RI, Rosato FE, Biermann WA, Weiss SM, Pajak TF (1984) Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54:1991–1998

    Article  PubMed  CAS  Google Scholar 

  • Whittington R, Neuberg D, Tester WJ, Benson AB 3rd, Haller DG (1995) Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 13:227–232

    PubMed  CAS  Google Scholar 

  • Wilkowski R, Rau H, Bruns C, Wagner A, Sauer R, Hohenberger W, Koelbl O, Heinemann V (2006) Randomized phase II trial comparing gemcitabine/cisplatin-based chemoradiotherapy (CRT) to 5-FU-based CRT in patients with locally advanced pancreatic cancer. J Clin Oncol (Meeting Abstracts) 24:4038

    Google Scholar 

  • Willett CG, Del Castillo CF et al (2005) Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 241:295–299

    Article  PubMed Central  PubMed  Google Scholar 

  • Yeo TP, Hruban RH et al (2002) Pancreatic cancer. Curr Probl Cancer 26:176–275

    Article  PubMed  Google Scholar 

  • Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D (2007) Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Library 4:1–72

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Oncologie Radiothérapie, Hôpital Tenon, Assistance Publique – Hôpitaux de Paris, 4 rue de la Chine, 75020, Paris, France

    Florence Huguet

Authors
  1. Florence Huguet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florence Huguet .

Editor information

Editors and Affiliations

  1. , Radiological, Oncological, and Pathologi, Sapienza , Università di Roma, Polo Pontino, Latina, Italy

    Andrea Laghi

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Huguet, F. (2010). The Locally Advanced Nonmetastatic Cancer. In: Laghi, A. (eds) New Concepts in Diagnosis and Therapy of Pancreatic Adenocarcinoma. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2010_2

Download citation

  • DOI: https://doi.org/10.1007/174_2010_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-85380-0

  • Online ISBN: 978-3-540-85381-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation